Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.
Sanofi and Regeneron have cut to the front of the line in the race to develop a new class of cardio drugs, but now rival Amgen has made a chess move of its own, filing a patent-infringement lawsuit designed to block its rivals from reaching what's expected to be a blockbuster market.
Sanofi may be trailing in the sprint toward a herpes vaccine, but a new collaboration may give it the boost it needs to stay in the game.
Selecta Biosciences and the Juvenile Diabetes Research Foundation are widening their 2011 research collaboration for a Type 1 diabetes vaccine--and bringing in a little Big Pharma muscle, too.
India's rotavirus vaccines market is headed for a shake-up, and Sanofi's angling to get in on the action. It got one step closer this week, with its Indian affiliate commencing Phase III clinical trials for its own investigational vaccine.
Last week, Sanofi told the feds it had hired an outside law firm to dive into an anonymous whistleblower's accusations of corruption in the Middle East. But the company's proactive approach may not be enough to block a blow to its reputation, experts say.
Alnylam's in-development RNAi treatment successfully staved off nerve damage related to a rare disease in an ongoing study, the biotech said, early but promising results as the company heads into Phase III with partner Sanofi in tow.
As it works to refine its vaccine strategy for the event of an avian flu pandemic, the NIH is trialing Sanofi's H7N9 vaccine at a range of doses and with a variety of adjuvant combinations. And now, it has one that looks promising.
Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.
Unilife, the injectable technology provider, has inked a deal with Sanofi to be the French drugmaker's sole provider of cartridge-based wearable injectors for the next 15 years.